East Asia - Hong Kong

Conyers

We only have limited information for this firm. Consider the following firms which have provided more information:

‘Renowned for its familiarity with the financial and judicial environment in Hong Kong’, the ’knowledgeable and responsive’ team at Conyers is consequently able to provide ‘practical solutions for clients to deal with matters involving the relevant offshore jurisdictions efficiently’. Under the astute leadership of the ’very experienced’ Christopher Bickley the firm has gained most acclaim for its corporate and issuer side capital markets work, which was again underscored by Bickley’s recent representation of Chinese spirit maker’s JLD Group’s high-profile HK$5.3bn HKSE IPO. Richard Hall is also well regarded for corporate finance matters, as is Lilian Woo, who excels at handling global equity offerings. Mark Yeadon spearheads the office’s three-partner litigation offering that is particularly adept at handling cross-border family and shareholder disputes and restructuring. Within that group, Norman Hau is ‘very experienced in dealing with commercial and corporate disputes with PRC clients’, while Anna Lin has experience in working on complex and high-value share appraisal proceedings, directors liability disputes and professional negligence claims in various offshore jurisdictions. Consultant David Lamb also handles contentious corporate work as well as public company M&A.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • 'The team is practical and very responsive.'
  • 'The team is well-established and renowned for its familiarity with the financial and judicial environment in Hong Kong, which enables them to give practical solutions for clients to deal with matters involving the relevant offshore jurisdictions efficiently.'

Abbreviated data is displayed for this firm.

Key clients

  • 3D Medicines Inc.
  • Golden Wheel Tiandi Holdings Company Limited

Abbreviated data is displayed for this firm.

Work highlights

  • Advised ZJLD Group Inc., a Chinese spirit maker, in connection with its HK$5.3bn IPO on the Main Board of The Stock Exchange of Hong Kong Limited.
  • Advised biopharmaceutical 3D Medicines on its successful IPO on the Main Board of the Hong Kong Stock Exchange Limited raising approximately HK$408m.

Abbreviated data is displayed for this firm.